Molecular imaging as a tool for translating breast cancer science

Breast Cancer Research

Volumn 10, Issue SUPPL. 1, 2008, Pages

  Mankoff, David A ^a  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BREAST TUMOR; DIAGNOSTIC IMAGING; GENETICS; HUMAN; PHYSIOLOGY; RADIOGRAPHY; REPORTER GENE; REVIEW; SCINTISCANNING; TRANSGENE;

ANIMALS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; GENES, REPORTER; HUMANS; TRANSGENES;

EID: 58249084323     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2126     Document Type: Review

References (158)

1. Hutter H. Fluorescent reporter methods. Methods Mol Biol 2006, 351:155-173.
2. Blasberg RG. Imaging update: new windows, new views. Clin Cancer Res 2007, 13:3444-3448.
3. Mankoff DA. A definition of molecular imaging. J Nucl Med 2007, 48:18N. 21N.
4. Mankoff DA, O'Sullivan F, Barlow WE, Krohn KA. Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol 2007, 14:398-405.
5. Benard F, Turcotte E. Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res 2005, 7:153-162.
6. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008,
7. Welch DR. Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 2004, 6:61-64.
8. Bloch SH, Dayton PA, Ferrara KW. Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng Med Biol Mag 2004, 23:18-29.
9. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res 2005, 7:149-152.
10. Lehman CD, Schnall MD. Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res 2005, 7:215-219.
11. Mankoff D. Imaging in breast cancer - breast cancer imaging revisited. Breast Cancer Res 2005, 7:276-278.
12. Berger F, Gambhir SS. Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. Breast Cancer Res 2001, 3:28-35.
13. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, . American Cancer Society Breast Cancer Advisory Group American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57:75-89. American Cancer Society Breast Cancer Advisory Group.
14. Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD, . ACRIN Trial 6667 Investigators Group MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007, 356:1295-1303. ACRIN Trial 6667 Investigators Group.
15. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006, 239:361-374.
16. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM. Antiangiogenic and anti-tumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24:769-777.
17. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007, 25:1-13.
18. Sosnovik DE, Weissleder R. Emerging concepts in molecular MRI. Curr Opin Biotechnol 2007, 18:4-10.
19. Morse DL, Galons JP, Payne CM, Jennings DL, Day S, Xia G, Gillies RJ. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 2007, 20:602-614.
20. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, Stopeck A. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004, 6:831-837.
21. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005, 7:287-326.
22. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H NMR spectroscopy - a pilot study at 4 T. Radiology 2004, 233:424-431.
23. Mankoff DA, Eubank WB. Current and future use of positron emission tomography (PET) in breast cancer. J Mammary Gland Biol Neoplasia 2006, 11:125-136.
24. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005, 23:1664-1673.
25. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007, 13:3460-3469.
26. Cherry SR. The 2006 Henry N. Wagner Lecture: Of mice and men (and positrons) - advances in PET imaging technology. J Nucl Med 2006, 47:1735-1745.
27. Rosen EL, Turkington TG, Soo MS, Baker JA, Coleman RE. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 2005, 234:527-534.
28. Alessio AM, Kinahan PE, Cheng PM, Vesselle H, Karp JS. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am 2004, 42:1017-32. vii..
29. Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, Butler J, Mehta R. Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 2005, 7:279-285.
30. Mahmood U. Near infrared optical applications in molecular imaging. Earlier, more accurate assessment of disease presence, disease course, and efficacy of disease treatment. IEEE Eng Med Biol Mag 2004, 23:58-66.
31. Henriquez NV, van Overveld PG, Que I, Buijs JT, Bachelier R, Kaijzel EL, Löwik CW, Clezardin P, Pluijm G. Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis 2007, 24:699-705.
32. Mendelson EB. Problem-solving ultrasound. Radiol Clin North Am 2004, 42:909-18. vii..
33. Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng 2007, 9:415-447.
34. Huang SW, Kim K, Witte RS, Olafsson R, O'Donnell M. Inducing and imaging thermal strain using a single ultrasound linear array. IEEE Trans Ultrason Ferroelectr Freq Control 2007, 54:1718-1720.
35. Brenner RJ, Parisky Y. Alternative breast-imaging approaches. Radiol Clin North Am 2007, 45:907-923. viii..
36. Chodosh LA, Cardiff RD. In vivo imaging of the mammary gland: the shape of things to come. J Mammary Gland Biol Neoplasia 2006, 11:101-102.
37. Kety SS. Basic principles for the quantitative estimation of regional cerebral blood flow. Res Publ Assoc Res Nerv Ment Dis 1985, 63:1-7.
38. Rajendran JG, Mankoff DA. Positron emission tomography imaging of hypoxia and blood flow in tumors. Cancer Drug Discovery and Development: In vivo Imaging of Cancer 2006, 47-71. Totowa, NJ: Humana Press, Shields AF, Price P.
39. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003, 44:1806-1814.
40. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging 2007, 26:235-249.
41. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003, 17:509-520.
42. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006, 24:3293-3298.
43. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005, 30:324-341.
44. Strecker R, Scheffler K, Buchert M, Mross K, Drevs J, Hennig J. DCE-MRI in clinical trials: data acquisition techniques and analysis methods. Int J Clin Pharmacol Ther 2003, 41:603-605.
45. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 2007, 14:77-91.
46. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003, 76(Spec No 1):S87-91.
47. Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW. A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res 2006, 12:281-288.
48. Aliaga A, Rousseau JA, Cadorette J, Croteau E, van Lier JE, Lecomte R, Bénard F. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 2007, 9:144-150.
49. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S103-111.
50. Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?. Mol Imaging Biol 2003, 5:281-285.
51. Matsumura A, Isobe T, Takano S, Kawamura H, Anno I. Non-invasive quantification of lactate by proton MR spectroscopy and its clinical applications. Clin Neurol Neurosurg 2005, 107:379-384.
52. Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR. In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 2006, 19:504-512.
53. Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T, Scarabino T. Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol 2007, 17:1651-1662.
54. Leach MO. Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Res earch. Phys Med Biol 2006, 51:R61-82.
55. Mountford C, Lean C, Malycha P, Russell P. Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging 2006, 24:459-477.
56. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol 2007, 63:351-360.
57. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003, 2:497-507.
58. Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 2007, 4:330-345.
59. Haddadin IS, McIntosh A, Meisamy S, Corum C, Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 2007,
60. Tannock IF. Cell proliferation. The Basic Science of Oncology 1992, 154-177. New York: McGraw-Hill, Tannock IF, Hill RP.
61. Cleaver JE. Thymidine metabolism and cell kinetics. Frontiers Biol 1967, 6:43-100.
62. Mankoff DA, Shields AF, Link JM, Graham MM, Muzi M, Peterson LM, Eary JF, Krohn KA. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med 1999, 40:614-624.
63. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005, 43:153-167.
64. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998, 4:1334-1336.
65. Been LB, Elsinga PH, de Vries J, Cobben DC, Jager PL, Hoekstra HJ, Suurmeijer AJ. Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 2006, 32:39-43.
66. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007, 34:1339-1347.
67. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006, 8:36-42.
68. Smyczek-Gargya B, Fersis N, Dittmann H, Vogel U, Reischl G, Machulla HJ, Wallwiener D, Bares R, Dohmen BM. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004, 31:720-724.
69. Blankenberg F, Ohtsuki K, Strauss HW. Dying a thousand deaths. Radionuclide imaging of apoptosis. Q J Nucl Med 1999, 43:170-176.
70. Wiele C, Lahorte C, Vermeersch H, Loose D, Mervillie K, Steinmetz ND, Vanderheyden JL, Cuvelier CA, Slegers G, Dierck RA. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol 2003, 21:3483-3487.
71. Schoenberger J, Bauer J, Moosbauer J, Eilles C, Grimm D. Innovative strategies in in vivo apoptosis imaging. Curr Med Chem 2008, 15:187-194.
72. Tait JF, Smith C, Blankenberg FG. Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J Nucl Med 2005, 46:807-815.
73. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007, 13:443-450.
74. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 1995, 13:1470-1477.
75. Ishiwata K, Enomoto K, Sasaki T, Elsinga PH, Senda M, Okazumi S, Isono K, Paans AM, Vaalburg W. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med 1996, 37:279-285.
76. Hübner KF, Thie JA, Smith GT, Kabalka GW, Keller IB, Kliefoth AB, Campbell SK, Buonocore E. Positron emission tomography (PET) with 1-aminocyclobutane-1-[(11)C]carboxylic acid (1-[(11)C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging 1998, 1:165-173.
77. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 2006, 6:821-829.
78. Stanwell P, Mountford C. In vivo proton MR spectroscopy of the breast. Radiographics 2007, 27(Suppl 1):S253-266.
79. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007, 8:822-830.
80. Lupu R, Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?. Endocrinology 2006, 147:4056-4066.
81. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007, 51:1511-1520. discussion 1520-1521..
82. Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn 2007, 7:659-672.
83. Zheng QH, Stone KL, Mock BH, Miller KD, Fei X, Liu X, Wang J-Q, Glick-Wilson BE, Sledge GW, Hutchins GD. [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol 2002, 29:803-807.
84. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007, 72:7-25.
85. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Baja-monde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
86. Katzenellenbogen J. The pharmacology of steroid radiophar-maceuticals: specific and non-specific binding and uptake selectivity. Radiopharmaceuticals: Chemistry and Pharmacology 1992, 297-331. New York: Marcel Dekker, Nunn A.
87. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 1997, 17:1573-1576.
88. Katzenellenbogen JA. Designing steroid receptor-based radio-tracers to image breast and prostate tumors. J Nucl Med 1995, 36(6 Suppl):8S-13S.
89. Rijks LJ, Busemann Sokole E, Stabin MG, de Bruin K, Janssen AG, van Royen EA. Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging. Eur J Nucl Med 1998, 25:40-47.
90. Zielinski JE, Larner JM, Hoffer PB, Hochberg RB. The synthesis of 11 beta-methoxy-[16 alpha-123I] iodoestradiol and its interaction with the estrogen receptor in vivo and in vitro. J Nucl Med 1989, 30:209-215.
91. Cummins CH. Radiolabeled steroidal estrogens in cancer research. Steroids 1993, 58:245-259.
92. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984, 25:1212-1221.
93. Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol 1999, 26:905-913.
94. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006, 24:2793-2799.
95. Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA. Breast cancer: PET imaging of estrogen receptors. Radiology 1988, 169:45-48.
96. Peterson LM, Mankoff DA, Lawton TJ, Yagle KJ, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression of breast cancer with PET and [F-18']-fluorestradiol. J Nucl Med 2008,
97. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, Detert DD, Cutler PD, Katzenellenbogen JA, Welch MJ. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995, 36:1766-1774.
98. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001, 19:2797-2803.
99. Linden HM, Link JM, Stekhova S, Livingston RB, Gralow JR, Ellis GK, Schubert EK, Peterson LM, Krohn KA, Mankoff DA. Serial 18F-fluoroestradiol positron emission tomography (FES PET) measures estrogen receptor binding during endocrine therapy. Breast Cancer Res Treat 2005,
100. Dehdashti F, McGuire AH, Brocklin HFV, Siegel BA, Andriole DP, Griffeth LK, Pomper MG, Katzenellenbogen JA, Welch MJ. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-nonproges-terone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991, 32:1532-1537.
101. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 1998, 42:8-17.
102. Verhagen A, Studeny M, Luurtsema G, Visser GM, De Goeij CC, Sluyser M, Nieweg OE, Ploeg E, Go KG, Vaalburg W. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 1994, 21:941-952.
103. Zhou D, Carlson KE, Katzenellenbogen JA, Welch MJ. Bromine- and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity. J Med Chem 2006, 49:4737-4744.
104. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, . American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. American Society of Clinical Oncology.
105. Bogdanov A, Kang HW, Querol M, Pretorius PH, Yudina A. Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo. Bioconjug Chem 2007, 18:1123-1130.
106. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007, 34:850-858.
107. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
108. Perik PJ, Lub-De Hooge MN, Gietema JA, Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
109. Pnwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R, Mishra AK. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 2005, 4:854-860.
110. Engfeldt T, Orlova A, Tran T, Bruskin A, Widström C, Karlström AE, Tolmachev V. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007, 34:722-733.
111. Tolmachev V, Nilsson FY, Widström C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006, 47:846-853.
112. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006, 47:793-796.
113. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:701-706.
114. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007, 48:1357-1368.
115. de Korte MA, de Vries EG, Lub-de Hooge MN, Jager PL, Gietema JA, Graaf WT, Sluiter W, van Veldhuisen D, Suter T, Sleijfer D. (111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007, 43:2046-2051.
116. Dijkers E, Lub-de Hooge MN, Kosterink JG, Jager PL, Brouwers AH, Perk LR, van Dongen GA, de Vries EG. Characterization of 89Zf-trastuzumab for clinical HER2 immunoPET imaging. J Clin Oncol 2007, 25:140s.
117. Achilefu S. Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res Treat 2004, 3:393-409.
118. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003, 63:2723-2727.
119. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, Kim S, Cho EJ, Yoon HG, Suh JS, Cheon J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007, 13:95-99.
120. Liu J, Li J, Rosol TJ, Pan X, Voorhees JL. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol 2007, 52:4739-4747.
121. Rosenthal EL, Kulbersh BD, King T, Chaudhuri TR, Zinn KR. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther 2007, 6:1230-1238.
122. Winnard P, Raman V. Real time non-invasive imaging of receptor-ligand interactions in vivo. J Cell Biochem 2003, 90:454-463.
123. Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 2007, 13:2936-2945.
124. Loo C, Lowery A, Halas N, West J, Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 2005, 5:709-711.
125. Hilger I, Leistner Y, Berndt A, Fritsche C, Haas KM, Kosmehl H, Kaiser WA. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol 2004, 14:1124-1129.
126. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004, 22:843-850.
127. Copland JA, Eghtedari M, Popov VL, Kotov N, Mamedova N, Motamedi M, Oraevsky A. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol 2004, 6:341-349.
128. Sutherland R. Tumor hypoxia and gene expression. Acta Oncologica 1998, 37:567-574.
129. Teicher B. Hypoxia and drug resistance. Cancer Metastasis Rev 1994, 13:139-168.
130. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglu-cose positron emission tomography imaging. Clin Cancer Res 2004, 10:2245-2252.
131. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007, 17:861-872.
132. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
133. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M. Patterns of {alpha}v{beta}3 expression in primary and metastatic human breast cancer as shown by 18F-galacto-RGD PET. J Nucl Med 2008, 49:255-259.
134. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006, 12:3942-3949.
135. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993, 53:977-984.
136. Ciarmiello A, Vecchio SD, Silvestro P, Potenta M, Carriero M, Thomas R, Botti G, D'Aiuto G, Salvatore M. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998, 16:1677-1683.
137. Hendrikse NH, de Vries EG, Franssen EJ, Vaalburg W, Graaf WT. In vivo measurement of [11C]verapamil kinetics in human tissues. Eur J Clin Pharmacol 2001, 56:827-829.
138. Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett D, Bear HD, McCumiskey JF. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol 2007, 34:823-831.
139. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005, 77:503-514.
140. Mohs AM, Lu ZR. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv 2007, 4:149-164.
141. Serganova I, Blasberg R. Reporter gene imaging: potential impact on therapy. Nucl Med Biol 2005, 32:763-780.
142. Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, Gambhir SS. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther 2005, 12:329-339.
143. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683-693.
144. Ntziachristos V. Fluorescence molecular imaging. Annu Rev Biomed Eng 2006, 8:1-33.
145. Blasberg RG, Tjuvajev JG. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med 1999, 43:163-169.
146. Gambhir SS, Barrio JR, Herschman HR, Phelps ME. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 1999, 26:481-490.
147. Yaghoubi SS, Gambhir SS. Measuring herpes simplex virus thymidine kinase reporter gene expression in vitro. Nat Protoc 2006, 1:2137-2142.
148. Blasberg RG. In vivo molecular-genetic imaging: multi-modality nuclear and optical combinations. Nucl Med Biol 2003, 30:879-888.
149. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004, 9:436-442.
150. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005, 205:194-205.
151. Gilad AA, Winnard PT, van Zijl PC, Bulte JW. Developing MR reporter genes: promises and pitfalls. NMR Biomed 2007, 20:275-290.
152. Zhang SJ, Wu JC. Comparison of imaging techniques for tracking cardiac stem cell therapy. J Nucl Med 2007, 48:1916-1919.
153. Acton PD, Zhou R. Imaging reporter genes for cell tracking with PET and SPECT. Q J Nucl Med Mol Imaging 2005, 49:349-360.
154. Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther 2002, 2:55-66.
155. Aboagye EO, Price PM. Use of positron emission tomography in anticancer drug development. Invest New Drugs 2003, 21:169-181.
156. Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005, 11:7967-7985.
157. Aberle DR, Chiles C, Gatsonis C, Hillman BJ, Johnson CD, McClennan BL, Mitchell DG, Pisano ED, Schnall MD, Sorensen AG, . American College of Radiology Imaging Network Imaging and cancer: research strategy of the American College of Radiology Imaging Network. Radiology 2005, 235:741-751. American College of Radiology Imaging Network.
158. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005, 35:84-99.